NO933452D0 - Et terapeutisk middel for parkinson's sykdom - Google Patents
Et terapeutisk middel for parkinson's sykdomInfo
- Publication number
- NO933452D0 NO933452D0 NO933452A NO933452A NO933452D0 NO 933452 D0 NO933452 D0 NO 933452D0 NO 933452 A NO933452 A NO 933452A NO 933452 A NO933452 A NO 933452A NO 933452 D0 NO933452 D0 NO 933452D0
- Authority
- NO
- Norway
- Prior art keywords
- straight
- alkoxy
- branched chain
- naphthyl
- halogen
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000001624 naphthyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- -1 nitro, amino Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- ICCBZGUDUOMNOF-UHFFFAOYSA-N azidoamine Chemical group NN=[N+]=[N-] ICCBZGUDUOMNOF-UHFFFAOYSA-N 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Radar Systems Or Details Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25783492 | 1992-09-28 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO933452D0 true NO933452D0 (no) | 1993-09-27 |
| NO933452L NO933452L (no) | 1994-03-29 |
| NO304946B1 NO304946B1 (no) | 1999-03-08 |
Family
ID=17311787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO933452A NO304946B1 (no) | 1992-09-28 | 1993-09-27 | Xantinderivat samt dets anvendelse |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0590919B1 (no) |
| JP (1) | JP2613355B2 (no) |
| AT (1) | ATE188216T1 (no) |
| CA (1) | CA2107014C (no) |
| DE (1) | DE69327438T2 (no) |
| DK (1) | DK0590919T3 (no) |
| ES (1) | ES2141137T3 (no) |
| GR (1) | GR3032972T3 (no) |
| NO (1) | NO304946B1 (no) |
| PT (1) | PT590919E (no) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6781194A (en) * | 1993-05-03 | 1994-11-21 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| AU1823895A (en) * | 1994-02-23 | 1995-09-11 | Kyowa Hakko Kogyo Co. Ltd. | Xanthine derivative |
| US5620676A (en) * | 1994-03-08 | 1997-04-15 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically active ATP analogs |
| US5922751A (en) | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
| US5591776A (en) | 1994-06-24 | 1997-01-07 | Euro-Celtique, S.A. | Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV |
| GB9415529D0 (en) * | 1994-08-01 | 1994-09-21 | Wellcome Found | Phenyl xanthine derivatives |
| EP0814809B1 (en) | 1994-12-13 | 2003-08-13 | Euroceltique S.A. | Aryl thioxanthines |
| CA2206804C (en) | 1994-12-13 | 2002-03-19 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
| US6166041A (en) | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
| US6075016A (en) | 1996-04-10 | 2000-06-13 | Euro-Celtique S.A. | 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity |
| US5864037A (en) | 1996-06-06 | 1999-01-26 | Euro-Celtique, S.A. | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity |
| GB9703044D0 (en) * | 1997-02-14 | 1997-04-02 | Glaxo Group Ltd | Phenyl xanthine esters and amides |
| US6727259B2 (en) | 1997-09-05 | 2004-04-27 | Kyowa Hakko Kogyo Co., Ltd. | Remedial agent for neural degeneration |
| WO1999030715A1 (fr) * | 1997-12-15 | 1999-06-24 | Kyowa Hakko Kogyo Co., Ltd. | Agents prophylactiques contre les troubles du sommeil et remedes aux troubles du sommeil |
| GB9817623D0 (en) | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| AR023966A1 (es) * | 1999-05-12 | 2002-09-04 | Fujisawa Pharmaceutical Co | Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion |
| EP1234576B1 (en) * | 1999-10-29 | 2006-03-08 | Kyowa Hakko Kogyo Co., Ltd. | Pharmaceutical composition for eating disorders |
| ATE430749T1 (de) * | 2001-02-24 | 2009-05-15 | Boehringer Ingelheim Pharma | Xanthinderivate verwendung als arzneimittel sowie deren verfahren zur deren herstellung |
| TWI330183B (no) | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| US20060106040A1 (en) * | 2002-12-19 | 2006-05-18 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| CN100395245C (zh) * | 2003-05-09 | 2008-06-18 | 协和发酵工业株式会社 | 微晶 |
| TW200507882A (en) * | 2003-07-17 | 2005-03-01 | Kyowa Hakko Kogyo Kk | Solid formulations |
| TWI346114B (en) * | 2003-09-29 | 2011-08-01 | Method for stabilization of diarylvinylene compounds | |
| ES2532479T3 (es) | 2004-01-28 | 2015-03-27 | Kyowa Hakko Kirin Co., Ltd. | Agentes para el tratamiento de la migraña |
| JP5188066B2 (ja) * | 2004-12-03 | 2013-04-24 | 協和発酵キリン株式会社 | 薬物依存症の予防および／または治療剤 |
| KR20090094465A (ko) * | 2006-12-22 | 2009-09-07 | 슈바르츠 파르마 악티엔게젤샤프트 | 선택적 ａ2ａ 수용체 안타고니스토로서의 8-알키닐잔틴 유도체 |
| US8871751B2 (en) | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
| WO2012070601A1 (ja) * | 2010-11-24 | 2012-05-31 | ヤマサ醤油株式会社 | 新規な２－アルキニル－ｎ９－プロパギルアデニンおよびその医薬用途 |
| RU2477726C1 (ru) * | 2011-10-18 | 2013-03-20 | Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") | Замещенные феноксиуксусные кислоты, их эфиры и амиды, включающие 2,6-диоксо-2,3,6,7-тетрагидро-1н-пурин-8-иловый фрагмент, - антагонисты аденозинового a2a рецептора и их применение |
| RU2480469C1 (ru) * | 2012-02-03 | 2013-04-27 | Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") | Замещенные 1,3-диэтил-8-винил-7-метил-3,7-дигидро-пурин-2,6-дионы-антагонисты аденозинового a2a рецептора и их применение |
| CN104744464B (zh) * | 2013-11-15 | 2016-09-21 | 南京华威医药科技开发有限公司 | 伊曲茶碱晶型 |
| CN105884776A (zh) * | 2014-11-05 | 2016-08-24 | 南京瑞天医药科技有限公司 | 一种伊曲茶碱的新晶型及其制备方法 |
| WO2016148260A1 (ja) * | 2015-03-17 | 2016-09-22 | 協和発酵キリン株式会社 | 医薬組成物 |
| EP3272349A4 (en) * | 2015-03-19 | 2018-09-19 | Kyowa Hakko Kirin Co., Ltd. | Therapeutic and/or prophylactic agent for lewy body diseases |
| WO2020125779A1 (en) * | 2018-12-21 | 2020-06-25 | Sunshine Lake Pharma Co., Ltd. | 8-substituted styryl xanthine derivatives and uses thereof |
| CN111333648B (zh) * | 2019-04-24 | 2021-05-11 | 东莞市东阳光新药研发有限公司 | 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途 |
| CN110041331B (zh) * | 2019-05-17 | 2020-08-07 | 广东东阳光药业有限公司 | 苯乙烯基黄嘌呤衍生物及其用途 |
| WO2021093701A1 (en) * | 2019-11-11 | 2021-05-20 | Sunshine Lake Pharma Co., Ltd. | 8-substituted styryl xanthine derivatives and uses thereof |
| CN111072663B (zh) * | 2019-12-12 | 2021-10-01 | 广东东阳光药业有限公司 | 8-取代的苯乙烯基黄嘌呤衍生物及其用途 |
| CN111018856B (zh) * | 2019-12-12 | 2021-10-01 | 广东东阳光药业有限公司 | 8-取代的苯乙烯基黄嘌呤衍生物及其用途 |
| AU2021235803A1 (en) * | 2020-03-10 | 2022-09-29 | Marvel Biotechnology | Purine compounds for treating disorders |
| CN111548351B (zh) * | 2020-06-22 | 2021-03-12 | 连云港贵科药业有限公司 | 一种伊曲茶碱的合成方法 |
| CN113248505B (zh) * | 2021-06-09 | 2021-09-21 | 南京安杰新生物医药有限公司 | 伊曲茶碱去甲基杂质的制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2729642A (en) * | 1954-08-13 | 1956-01-03 | Chattanooga Medicine Co | Water soluble salts of 8-(para-aminobenzyl) caffeine and method for their preparation |
| CA929519A (en) * | 1969-07-30 | 1973-07-03 | Schweiss Dieter | Xanthine compounds and means for obtaining the same |
| US3624215A (en) * | 1970-06-25 | 1971-11-30 | Abbott Lab | 8-substituted theophyllines as anti-anxiety agents |
| US3624216A (en) * | 1970-06-25 | 1971-11-30 | Abbott Lab | 8-substituted theophyllines as anti-inflammatory agents |
| US3900474A (en) * | 1973-05-14 | 1975-08-19 | Kendall & Co | Trifluoroalkyl, fluorobenzyl, pentafluorobenzyl, fluorobenzenesulfonyl, and pentafluorobenzenesulfonyl theophyllines |
| ES506046A0 (es) * | 1981-10-06 | 1983-02-01 | Invest Tecnica Aplicada | Procedimiento de obtencion de nuevas xantinas con actividad farmacologica |
| US4452788A (en) * | 1982-04-21 | 1984-06-05 | Warner-Lambert Company | Substituted 8-phenylxanthines |
| FR2531085A1 (fr) * | 1982-07-28 | 1984-02-03 | Adir | Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
| US4593095A (en) * | 1983-02-18 | 1986-06-03 | The Johns Hopkins University | Xanthine derivatives |
| US4696932A (en) * | 1984-10-26 | 1987-09-29 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically-active xanthine derivatives |
| GB8510758D0 (en) * | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
| HU197746B (en) * | 1985-09-05 | 1989-05-29 | Sandoz Ag | Process for producing xantin derivatives and pharmaceutical compositions containing them |
| US4755517A (en) * | 1986-07-31 | 1988-07-05 | Warner-Lambert Company | Derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
| US4783530A (en) * | 1986-11-13 | 1988-11-08 | Marion Laboratories, Inc. | 8-arylxanthines |
| US4968672A (en) * | 1987-01-02 | 1990-11-06 | The United States Of America As Represented By The Department Of Health And Human Services | Adenosine receptor prodrugs |
| DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
| JPH06102662B2 (ja) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
| FR2665636B1 (fr) * | 1990-08-10 | 1994-10-07 | Adir | Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer. |
| WO1992006976A1 (fr) * | 1990-10-18 | 1992-04-30 | Kyowa Hakko Kogyo Co., Ltd. | Derive de xanthine |
| CA2093403C (en) * | 1992-04-08 | 1999-08-10 | Fumio Suzuki | Therapeutic agent for parkinson's disease |
-
1993
- 1993-09-22 JP JP5236176A patent/JP2613355B2/ja not_active Expired - Lifetime
- 1993-09-27 CA CA002107014A patent/CA2107014C/en not_active Expired - Lifetime
- 1993-09-27 NO NO933452A patent/NO304946B1/no not_active IP Right Cessation
- 1993-09-28 ES ES93307654T patent/ES2141137T3/es not_active Expired - Lifetime
- 1993-09-28 DE DE69327438T patent/DE69327438T2/de not_active Expired - Lifetime
- 1993-09-28 DK DK93307654T patent/DK0590919T3/da active
- 1993-09-28 PT PT93307654T patent/PT590919E/pt unknown
- 1993-09-28 AT AT93307654T patent/ATE188216T1/de not_active IP Right Cessation
- 1993-09-28 EP EP93307654A patent/EP0590919B1/en not_active Expired - Lifetime
-
2000
- 2000-03-16 GR GR20000400672T patent/GR3032972T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0590919A1 (en) | 1994-04-06 |
| NO304946B1 (no) | 1999-03-08 |
| ES2141137T3 (es) | 2000-03-16 |
| NO933452L (no) | 1994-03-29 |
| JP2613355B2 (ja) | 1997-05-28 |
| CA2107014A1 (en) | 1994-03-29 |
| PT590919E (pt) | 2000-04-28 |
| ATE188216T1 (de) | 2000-01-15 |
| JPH06211856A (ja) | 1994-08-02 |
| DE69327438D1 (de) | 2000-02-03 |
| DK0590919T3 (da) | 2000-04-17 |
| GR3032972T3 (en) | 2000-07-31 |
| DE69327438T2 (de) | 2000-06-21 |
| EP0590919B1 (en) | 1999-12-29 |
| CA2107014C (en) | 2000-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO933452L (no) | Et terapeutisk middel for Parkinson's sykdom | |
| ATE216584T1 (de) | Xanthine-derivate als antidepressiva | |
| DE69021472D1 (de) | Pyrazolderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellung. | |
| DK0412404T3 (da) | Thiazolderivater, fremgangsmåder til fremstilling deraf og farmaceutiske præparater omfattende derivaterne | |
| DE69230163D1 (de) | Thiazolylbenzofuranderivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten | |
| ATE52498T1 (de) | Amidderivate. | |
| MX9800577A (es) | Derivados de 4,5-diaril oxazol. | |
| BR1100636A (pt) | Agente terapêutico para o mal de parkinson, e, derivado da xantina | |
| HUP0002272A2 (hu) | Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| EP1034783A4 (en) | AMIDE DERIVATIVES | |
| HUP0202237A2 (hu) | Amin, módosított pszeudomicin vegyületek, azokat tartalmazó gyógyászati készítmény és alkalmazásuk | |
| PT87954A (pt) | Processo para a preparacao de composicoes farmaceuticas contendo derivados de dioxopiperidina, com efeito antipsicotico | |
| ATE139767T1 (de) | Verfahren zur herstellung 5-pyrazolomerkaptan- derivate und dessen zwischenprodukte | |
| ATE165829T1 (de) | Nootrope wirkstoffe | |
| ATE266648T1 (de) | Heterocyclische anthracyclinonderivate | |
| MY101878A (en) | 1,3,4-thiadiazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |